Head and Neck Cancer Drugs Market, By Drug Class (Chemotherapy, Immunotherapy, and Targeted Therapy), By Sales Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Stores), and By Geography (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa)

Published In : Jun 2023

Code : CMI530

Pages :130

Formats :

Excel and PDF

Industry : Pharmaceutical

Market News

Global Head and Neck Cancer Drugs Market: Key Developments

In April 2023, Eisai launched “Made of More,” a new campaign to support and create a community among people with head and neck cancer. Moreover, Eisai is currently testing its approved cancer drug Lenvima in combination with other oncology drugs in head and neck cancers.

In July 2022, International Centre for Recurrent Head & Neck Cancer (IReC) has been launched to accelerate research and improve patient outcomes. IReC also aims to set international standards in curative treatment, palliation, and supportive care of recurrent head and neck cancer to improve patient outcomes in the UK and beyond.

In February 2022, University of Cincinnati researchers launched a new clinical trial to examine if the combination of a localized radiation treatment and immunotherapy can be a better treatment for patients with recurrent head and neck cancer.

In February 2021, the U.S. FDA granted breakthrough therapy designation to Tipifarnib developed by Kura Oncology, Inc., for the treatment of patients with head and neck squamous cell carcinoma (HNSCC). This is a potent, selective, and orally administered drug.